null

Tralokinumab (Anti-IL13) Biosimilar Antibody

SKU:
HDBS0129
Product Type:
Biosimilar Antibody
Antibody Type:
Monoclonal Antibody
Protein:
IL-13
Reactivity:
Human
Host Species:
Chimeric Humanized
Isotype:
IgG4
€373
Frequently bought together:

Description

system_update_altDatasheet

Tralokinumab (Anti-IL13) Biosimilar Antibody (HDBS0129)

The Tralokinumab Biosimilar Anti-IL13 Antibody is a cutting-edge research tool designed for studying the interleukin-13 (IL-13) signaling pathway. This monoclonal antibody, engineered specifically for targeting IL-13, has been rigorously validated for use in a variety of applications, including ELISA, immunofluorescence, and flow cytometry.IL-13 is a key cytokine involved in allergic inflammation and immune responses. By blocking IL-13, researchers can gain insights into the mechanisms underlying allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis. Additionally, IL-13 has been implicated in the pathogenesis of certain cancers and inflammatory conditions, making this antibody an invaluable tool for investigating these disease processes.

With its high specificity and affinity for IL-13, the Tralokinumab Biosimilar Anti-IL13 Antibody offers researchers a reliable means of studying the IL-13 pathway and exploring its potential as a therapeutic target. Whether investigating basic mechanisms of immune regulation or developing novel treatments for IL-13-related disorders, this antibody is an essential tool for advancing biomedical research.